Actionable news
0
All posts from Actionable news
Actionable news in AFMD: AFFIMED N.V.,

Affimed Announces Significant Investment By An Existing Shareholder

The following excerpt is from the company's SEC filing.

– Affimed N.V. (Nasdaq: AFMD), a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, today announced that an existing shareholder has increased its position in the Company by purchasing 3.3 million shares. The Agreement was signed on Oct. 9, 2015 and will lead to an investment of $21.8 million (€ 19.2 million).

“This investment will help to ensure that Affimed is well positioned to achieve our goals and thereby create value for our shareholders,” said Florian Fischer, Ph.D., CFO of Affimed. “We are grateful for this renewe d long-term commitment, which is an important validation of our unique NK- and T-cell approaches via our proprietary bispecific TandAb technology.”

Affimed has leveraged its expertise in next-generation bi- and trispecific antibodies to build a pipeline of unencumbered clinical and preclinical assets. Affimed’s lead candidate, AFM13, a bispecific CD30/CD16A TandAb currently in Phase 2 development for Hodgkin’s lymphoma (HL), has already shown signs of therapeutic activity as monotherapy after only four weeks of treatment in difficult-to-treat (salvage) patients. In addition, AFM13 has shown potential for synergistic efficacy in combination with checkpoint inhibitors in preclinical studies, where tumors shrank by up to approximately 90%. The Company’s second clinical candidate, AFM11, a bispecific CD19/CD3 TandAb antibody, is currently in Phase 1 in patients with non-Hodgkin lymphoma (NHL) and acute lymphocytic leukemia (ALL). The additional...


More